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Once the Board has made its selection (see 
box), the ATTC Managing Director will inform the 
selected investor(s) in writing. If a decision is 
made during the course of the Board meeting 
and it’s possible to invite the selected firm(s) in 
to the meeting, congratulate them and discuss 
next steps in person, all the better! However, in 
some cases, the Board will have continual and 
legitimate concerns about the top candidates 
and will have asked for additional information 
after the presentations—resulting either in no 
company selected as a manufacturing and 
distribution partner or another month of 
discussions, deliberations, and compromises, 
within the Board and with the selected partner 
(see the example in the text box to the right). 
ATTC should inform the investors who have not 
been selected and thank them for their interest 






It is possible, even after the presentations, 
Q&A with the investors, and discussion 
amongst the Advisory Board, that they are not 
ready to make a decision. In Nigeria, the 
Advisory Board had reservations and felt they 
didn’t have sufficient information to make a 
decision based on the presentations and 
responses to their questions. As a result, the 
Advisory Board did not make a final decision at 
the end of the Board meeting. Instead, they 
continued to perform due diligence and asked 
for additional information from the investors, 
giving the Board a few extra weeks to analyze 
their options. The opposite was the case in 
Tanzania, where the Advisory Board was 
satisfied with the information presented by the 
investors and was able to make a unanimous 
decision on the final day of the Board meeting. 




ATTC  Aflasafe Technology Transfer and Commercialization 
BIP  Business Incubation Platform 
EOI  Expression of Interest 
IA  Intellectual Assets 
IITA  International Institute of Tropical Agriculture 
M&D  Manufacturing and Distribution 
PACA Partnership for Aflatoxin Control in Africa 
R&D  Research and Development 
TTLA  Technology Transfer Licensing Agreement 
USAID  United States Agency for International Development 
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I. Introduction 
The International Institute of Tropical Agriculture (IITA) has developed a unique solution, 
Aflasafe, to address aflatoxin contamination in major staple cereal crops in Africa. Through 
more than a decade-and-a-half of research and development, IITA and its partners have 
developed this product by identifying friendly fungi that are highly effective at reducing 
aflatoxin levels, then testing them in farmers’ fields. This testing has helped IITA create the 
best composition of Aflasafe for each country while providing data needed for the registration 
and regulatory process. The widespread application of Aflasafe in aflatoxin-affected areas 
has the potential to significantly increase quantities of aflatoxin-safe maize, sorghum, and 
groundnuts, and significantly reduce health effects of aflatoxin, including stunting in children 
and liver cancer. Through Aflasafe, IITA seeks to contribute not only to improving food safety 
but also increasing the income of smallholder farmers.  
 
To achieve these goals, IITA must widely deliver Aflasafe to agricultural value chain actors. 
However, developing an extensive production, distribution, and marketing operation 
throughout Africa to commercialize Aflasafe is not in line with the CGIAR Intellectual Assets 
(IA) Principles or the mandate of IITA as a non-profit research institution. After considering 
various options for manufacturing and distribution, IITA decided to pursue Aflasafe 
commercialization, led by the private sector and supported by the public sector, to turn this 
scientific innovation into a commercial product.  
Exhibit 1. Science to Scale Commercialization 
 
 
To facilitate the commercialization process, IITA received a grant from the Bill & Melinda 
Gates Foundation and the United States Agency for International Development (USAID) for 
implementation of a five-year initiative entitled Aflasafe Technology Transfer and 
Commercialization (ATTC), which is managed by IITA through the Business Incubation 
Platform (BIP). IITA hired Chemonics International, Inc. and Dalberg Advisors to support the 
implementation of ATTC. Aflasafe commercialization began in 2016 and has since 
expanded. Aflasafe is currently commercially registered and available in seven countries: 
Burkina Faso, The Gambia, Ghana, Kenya, Nigeria, Senegal, and Tanzania. As of October 
2019, 12 more countries across Africa are at different stages in the pipeline for eventual 
Aflasafe commercialization: Benin, Burundi, Cameroon, the Democratic Republic of the 
Congo, Ethiopia, Malawi, Mali, Mozambique, Rwanda, Zambia, Uganda, and Zimbabwe. In 
each country, ATTC researches the potential for commercialization, identifies and attracts 
potential investors, transfers the Aflasafe technology to an investor, and supports the 
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greatly preferred to hold all of the Board presentations in person. In addition to providing the 
option for translation if/as needed, and mitigating connectivity issues, an in-person 
presentation naturally provides more interactive 
Q&A sessions in addition to time for general 
interaction with the potential investors.  
 
By this stage, all of the investors who are finalists 
have undergone site visits and thorough due 
diligence. It is recommended to invite three 
(maximum of four, if warranted) investors to 
present to the Board. By now, you may have 
realized that one or more investors are not suited 
to be the selected M&D partner and therefore, it 
would not make sense to request an in-person 
presentation. It could also be that one of the 
investors is not qualified to carry out the 
manufacturing component but would be a valuable 
distribution partner. Speak with the investor to 
confirm their interest in distribution only, and if they are interested, invite them to participate 
in the presentation, making it clear what their interests and capabilities are.  
 
The Board will agree on the structure of the engagement with the investors, determining the 
length, format, and order of the presentations. Please see Annex E for a sample of the 
guidance letter provided to previous investors regarding the Advisory Board presentation 
and what to expect during the Q&A process (see box above for additional guidance).  
 
Step 10. Select the Investor 
 
Objective To select an investor or investors with the greatest potential to succeed in manufacturing 
and distributing Aflasafe 
Things to keep 
in mind 
 Did the presentations validate or change your assumptions of who was the strongest 
partner? 
 Is there any follow-up that is needed from an investor in order for the Advisory Board 
to make a decision? 





Led by the Advisory Board, and supported by the Team Leader  
 Ideally, the Advisory Board has sufficient information and can come to consensus and 
a decision at the end of the meeting. If not, there may be follow-up required from one 
or more investors, which could extend the investor selection timeline by 1-2 weeks. 
 
Following the investor presentations, the Board members will convene to discuss and 
deliberate, analyzing the strengths and weaknesses of the investors and the information 
gleaned from the presentations. The team can help by recapping the key decision points 
(these should also be on a slide within the Board presentation), as well as by summarizing 
any new pertinent information learned during the investor presentations. At this time, the 
Board will likely re-rank the investors. You can help spur the investor selection discussion by 




We would like for all investors to be able to put 
their best foot forward to give ATTC the 
clearest summary and most thorough view of 
their potential. Offer to provide guidance in 
preparing for the presentation to any potential 
investors that are interested. For example, 
investors can send their draft presentation for 
review and feedback, and/or rehearse with 
your team. However, do not give an unfair 
advantage to any one investor during this 
process. Your feedback should be 
constructive, to enhance the quality of the 
presentation, but not include tips on how to 
appeal to the Board. 
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 A review of the investor selection criteria 
 Proposed manufacturing sites 
 A review of the financial analysis 
 An overview of the licensing options 
 A ranking of the investors (with explanations of rankings) 
 Key considerations for the Board.  
 
The presentation given in person will most likely also include a section to discuss any 
outliers, special factors, or considerations to facilitate discussion with the Board. The data for 
the presentation comes from the work previously done during the due diligence phase and 
analysis of the business plans. To see a sample board presentation completed for Tanzania, 
please refer to the ATTC database/toolkit. 
 
The in-person presentation is helpful to frame the conversation and focus the Board 
members who are all juggling multiple initiatives. Thus, sufficient time for Q&A and an 
engaging dialogue with the Board is also critical, to ensure the Board members have a 
confidential space to ask any precursor questions before hearing the presentations from the 
companies. 
 
Step 9. Plan the Advisory Board Meetings with Potential Investors 
 
Objective To organize and facilitate the advisory board meeting in a way that provides 
sufficient information for the board to make a decision on the investor(s) and 
licensing options. 
Things to keep in mind  Will the Board convene for an in-person meeting to listen to the presentation, 
or will presentations only be held over videoconference (e.g. Skype) or phone?  
 How many investors will present out of the group of finalists?  
 What will be the order of the presentations? 
Projected timeline and 
resources 
Led by the Team Leader and Manager 
 The Team Leader should reach out to the advisory board at least two months 
in advance of the anticipated meeting date, as board members may have to 
travel 
 Preparations for the advisory board meeting will occur in tandem with the 
creation of the ATTC board presentation 
 The board meeting itself will take place usually over 2 days 
 
In addition to the presentation you will have created to summarize your analysis and 
recommendation, each of the investors will be asked to present their business plans to the 
Advisory Board. ATTC’s Advisory Board is comprised of members of the Bill & Melinda 
Gates Foundation, USAID, representatives of IITA senior management, and third-party 
advisors, such as the Partnership for Aflatoxin Control in Africa (PACA). Typically, at least 
one representative from each group attends the Board meeting. The ATTC Managing 
Director is the secretary of the Advisory Board. For IITA, a scientist and/or engineer may 
participate in the meeting to contribute their expertise as part of the investor review process 
when assessing understanding and ability to replicate manufacturing process. The Board 
also typically has a member that is able to analyze the financial information presented as 
part of the due diligence on investors. 
 
Having the Board members and investor representatives together in person is ideal because 
it reduces the potential for technological challenges that can occur when multiple people in 
different locations are dialing in, and allows Board members to meet the representatives, 
assess their commitment (or lack thereof), and ask questions directly. However, if resources 
and/or time are limited, or if an in-person meeting is not possible, meeting by Skype or 
phone is a second option. Due to connectivity and language issues, it has been found to be 
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manufacturing, distribution, and marketing efforts in such a way that the Aflasafe product will 
be available locally in an economically viable, sustainable, and independent way for many 
years to come.  
 
To enable the continued commercialization of Aflasafe and potentially support IITA or other 
CGIAR institutions in commercializing other products in the future, IITA, Chemonics, and 
Dalberg, under ATTC, have created four guides which outline the core processes of 
commercialization, i.e., how to take scientific research products to market. These guides 
include Market Assessment and Strategy Development, Investor Selection, Structuring the 
Business Relationship, and Implementation of the Business Development Strategy. A 
summary of the four guides is presented below in the order of the commercialization 
process. 
 
1. Market Assessment and Strategy Development: This guide describes the process 
that the ATTC initiative created for developing a commercialization strategy for 
Aflasafe, demonstrating how it can become a marketable farm input for sale in a 
specific country. The guide introduces the concept of commercialization and how it 
relates to IITA’s activities, outlines the desired outcomes of the market assessment 
and strategy development process, and suggests steps to be taken to develop a 
high-quality document featuring findings and conclusions backed by data—including 
the country context, market analysis, forecasts of Aflasafe uptake, a review of 
manufacturing potential, and identification of potential investors. The process should 
take approximately 4-6 months in total—if assigned to a dedicated team with no 
unforeseen delays. Once the commercialization strategy is in place, there should be 
a clear understanding of how to commercialize Aflasafe in the country by prioritizing 
core market segments that are sensitive to aflatoxin and thus more likely to adopt 
Aflasafe. The strategy also informs the capacities and expertise needed by an 
investor to undertake manufacturing, marketing, and distribution. 
 
2. Investor Selection: This guide discusses the ATTC initiative’s recommended 
process for sourcing potential partners, analyzing investor options, and ultimately 
selecting the investor(s) in a specific country with the best potential for success in the 
manufacturing, marketing, and distribution of Aflasafe. The initial ideas for partner 
identification will be generated during the strategy development process, with 
multiple submissions from partners and reviews by IITA, culminating in a final 
selection by an advisory board based on presentations and recommendations. The 
selection process should take approximately 4-6 months if completed efficiently and 
without delays.  
 
3. Structuring the Business Relationship: This guide shares the ATTC initiative’s 
experiences navigating CGIAR policies and practices and partner motivations to 
structure a business relationship with the private sector investor selected to become 
the manufacturing and distribution (M&D) partner for Aflasafe. It provides guidance to 
a non-legal audience on crafting the legal document needed for the transfer of the 
Aflasafe technology: a Technology Transfer Licensing Agreement (TTLA). The guide 
covers why this type of license agreement was selected by IITA as the core legal 
document for the process, provides questions to consider when tailoring the TTLA 
template, and offers insights into negotiations with M&D partners to date. The TTLA 
process can take 1-2 months, depending on the level of negotiation required. 
 
Investor Selection / Page 7 of 32
 
4. Implementation of the Business Development Strategy: This guide captures 
ATTC’s experiences working with the selected M&D partner to hand over valuable 
business knowledge developed throughout this process. This guide provides 
background information, lessons learned, and the recommended process for 
developing the key deliverables, including consumer profiles of potential buyers, a 
business case for the marketing of Aflasafe, and a handover memo for the selected 
partner. The guide addresses each of the key sections of these documents and 
shows their importance in facilitating the marketing and sales of Aflasafe to potential 
buyers. The development, consolidation, and handover of this information should 
take a total of 3-4 months using the standardized templates and tools. 
 
Please note that these guides are not exhaustive manuals, and thus should not be 
considered a complete list of steps to take. Also keep in mind that the approaches and 
guidance should be modified and contextualized for each target market and adjusted for 
changing dynamics. The guides have been designed with Aflasafe in mind but may be a 
starting point to adapt for other IITA or CGIAR products. As such, we have included 
considerations for products beyond Aflasafe throughout the guides. 
 
This guide is dedicated to the investor selection process and provides a detailed description 
of the recommended steps to be taken, including the sourcing of potential partners, 
analyzing the options, and selecting the partner with the best potential for success. The 
partner that is selected to receive the Aflasafe license must invest in the manufacturing and 
distribution of Aflasafe. Thus, we use both terms— partner and investor—throughout this 
guide. The goal of this guide is to identify the partner with the best prospect for investing in 
and succeeding with the manufacturing and distribution of Aflasafe. Choosing the right 
partner contributes to the success of the commercialization of Aflasafe. The guide also 
contains an annex of sample documents from prior work done in other countries that you can 
refer to throughout the process of selecting an investor.  
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Option 4: Joint venture by pre-selected investors.  
 
This became an option based on the request of an investor; however, it is unlikely to work in 
practice.  If no agreement can be reached, revert to dictated terms under the prior options, 




Once the best licensing arrangement is analyzed and determined, you can begin to prepare 
for the board presentation. 
 
Step 8. Develop the ATTC Team’s Presentation for the Advisory Board 
 
Objective To create a presentation which effectively summarizes the investor options and ATTC’s 
recommendation for investor and licensing option. 
Things to keep 
in mind 
 What decisions does the advisory board need to make at the end of the board 
meeting? How can we anticipate those and provide the necessary data to facilitate the 
decision making? 
 What are our recommendations that we want to communicate?  




Led by the Team Leader and Manager, supported by the Scientist and Financial Analyst 
 2-3 weeks to create the draft presentation, incorporate feedback from internal 
stakeholders into a final version, and submit to the advisory board; remember that we 
began drafting slides for the presentation during steps 4 and 5 while evaluating the 
business plans and audited financials 
 
Create a PowerPoint presentation which summarizes the key takeaways that the Board 
should consider when reviewing the candidates. This presentation is provided to the Board 
in advance of an in-person or Skype/phone meeting in which the Board convenes to review 
their options and hear directly from the candidates (addressed further below). There will 
likely be two versions of the presentation: the first is sent to the Board approximately one 
month in advance of the Board meeting and is similar to a visual summary of the primary 
information in each business plan, without any recommendations; the second is presented in 
person, and reflects any updates and feedback received leading up to the Board meeting, in 
addition to a summary comparison of the various companies and a recommendation for the 
Board to consider. The presentation to the Board and subsequent discussions with the 
Board is a great opportunity to share the analysis and any final recommendations. 
 
The presentation itself may contain sections including, but not limited to:  
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Option 2: Two competing investors each with a manufacturing & distribution licenses. 




Option 3: One manufacturing license plus one or more distribution license(s). In the 
case of multiple distribution licenses or the manufacturer’s insistence on distribution rights, 
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II. Overview of Investor Selection 
 
Getting Aflasafe to the last mile, in line with IITA’s mission, is most effective when working 
with and through the private sector. Without business acumen and experience, not to 
mention established and sustainable distribution channels and innovative marketing 
strategies, the product will never see the light of day. Successfully working with and through 
the private sector creates a cycle of financial support to regenerate and scale the operations 
of producing and distributing Aflasafe. 
 
A competitive selection process is necessary to ensure the most appropriate private sector 
partner is selected, ideally one whose strategic goals align with the IITA mission, and whose 
financial and management capacity can support development of this business line as a long-
term commitment. Although the product has been tested and proven with internationally 
recognized scientists at a research institute, it’s not a franchise nor turnkey operation. There 
is still significant market knowledge and strategy development required of the private sector 
partner. While the investor selection process is similar in some ways to a venture capital due 
diligence process, ensuring a competitive selection process is even more critical as IITA has 
a responsibility to the management of public goods and a reputation to protect by ensuring 
quality standards are upheld by the private sector partner. Open competition is healthy in 
that it promotes fairness and also drives innovation. During the investor selection process, 
support and engagement with the potential investors is recommended as a means to get to 
know the prospective partners, ensure they understand the operations and address any 
questions as they complete the applications without creating unfair advantages for any one 
potential investor along the way. The prospective investors must prove themselves and 
show that they value this opportunity and will fight to succeed in getting Aflasafe to market in 
the face of anticipated challenges. 
 
For additional background information on the entire commercialization process, and the 
importance of scaling through the private sector, please reference the overview sections in 
the Market Assessment and Strategy Development and Structuring the Business 
Relationship guides.  
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III. Roles and Responsibilities 
It is advantageous for the ATTC team members who will be conducting due diligence and 
analysis on the investor candidates to have the experience and knowledge of what is 
required to commercialize Aflasafe in a particular country. As such, some team members 
that were part of the commercialization strategy team for that country should also participate 
in the investor selection process, as possible, to be available to answer questions.  
 
Similar to the commercialization process to date, it is advisable to continue to draw upon the 
expertise of an external consulting strategy firm, to support the investor selection process. 
IITA is an internationally renowned scientific research institution. However, it does not have 
a private sector mandate and thus does not directly employ personnel with extensive 
business strategy experience and acumen. It behooves IITA to continue to partner with 
similarly strong, internationally recognized external consultancy and strategy companies to 
assess the capacities of investors. In addition, it may be important to add external resources 
with specialized expertise, such as financial analysis. In order to complete each step in the 
process detailed below, be sure to identify and mobilize the requisite human resources.  
 
Exhibit 2 below outlines the essential roles and responsibilities, but keep in mind that 
different resources may be required based on the specific needs of a country. The list below 
does not specify which team members should be brought in from an external consulting 
team, but ideally, they should have expertise in agribusiness, strategy and financial analysis. 
The Team Leader, Strategy Manager, and Financial Analyst all play important roles 
throughout the investor selection process, supported by other key roles. 
 
Exhibit 2. Illustrative Roles and Responsibilities for Investor Selection 
Role Illustrative Skills Responsibilities 
Team 
Leader 
Expertise in agribusiness market 
dynamics, strong management 
skills 
Overall quality control of the process. Represents ATTC 
during due diligence and in meetings with investors. 
Strategy 
Manager 
Experience in private sector 
engagement, knowledge of field 
research practices, critical thinking  
Coordinates and manages each step of the process. 




Experience in international 
development and economic 
research 
Supports the Strategy Manager with research tasks, 
brainstorming, and operational tasks. 
Financial 
Analyst 
Mastery of MS Excel, 
understanding of corporate finance 
principles 
Reviews the business plan financial model and audited 
financials, and develops financial slides for the Advisory 
Board presentations. 
Scientist Involvement in Aflasafe Research 
and Development (R&D) and/or 
testing, knowledge of country 
context 
Reviews the soundness of the overall commercialization 
plan in relation to Aflasafe. Reviews the ATTC board 
presentation and participates in the advisory board 
meeting 
Engineer Expertise in Aflasafe 
manufacturing facilities 
Participates in due diligence site visits and Advisory 
Board meeting to select the investor. Supports investor 
to design and inspect factory setup, identify and select 




Individuals mostly from outside 
your organization who bring 
diverse experience in agribusiness, 
science, experienced business 
acumen,  financial analysis and 
donor representative perspective  
Reviews investor options during Advisory Board meeting 
and selects investor. Serves as external checks and 
balances consistently across each investor selection 
process, ensuring the project team, in addition to IITA 
and donor representatives, are learning and applying 
lessons learned through the entire commercialization 
process. 
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Option 1: Nationwide exclusive licenses  
 
Option 1a: One nationwide exclusive license with a single investor for both 




Option 1b: One nationwide exclusive license with single investor for manufacturing 
partner and recommended distribution partnerships with additional companies 
 
This arrangement transpired in Tanzania where we had multiple competent applicants who 
offered different strengths. The investor chosen was clearly the strongest potential partner. 
The investor was given an exclusive license, but it was clear that given the large size the 
country, it would be advantageous for the investor to partner with some of the other 
applicants who had strong distribution networks. The Board determined that the selected 
investor should work directly with the other applicants who had networks that were 
complimentary to that of the selected investor. The selected investor is negotiating its 
distribution arrangements with the other applicants at the request of IITA. This approach will 
increase the investor’s geographic reach using partners who are already familiar with 
Aflasafe having gone through the application process. 
 
Option 1c: Nationwide exclusive distribution license and no manufacturing license in 
the country (yet) 
 
Our preference is to provide the manufacturing license to a firm within country. The 
additional investment in manufacturing operations creates more incentive for the licensee to 
succeed and is a better model for sustainability of operations. However, there may be 
instances where there is not a suitable company capable of manufacturing or it may be that 
no companies are interested in manufacturing. In this case, IITA could provide a distribution 
license only, if there is a nearby manufacturing operation.  
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The licensing options should be analyzed and 
presented to the Board as part of the Board 
presentation (see Step 8 below), with pros 
and cons of each option. By summarizing the 
potential options in the presentation which is 
submitted to the Board before Board meeting, 
frame the investor selection process and help 
guide the Board in thinking through their 
options. Note that after seeing all of the 
investor presentations, it is possible that an 
alternative arrangement may be identified 
during the Board meeting discussions, as 
happened in Tanzania (see box, and discussed in further detail below). The arrangement 
that the Board and investor(s) envision will be central to the negotiations and finalization of 
the TTLA, which is discussed in detail within the next guide. The tables below outline the 






For Tanzania, after the commercialization strategy, 
the Board assumed that there would be two licenses 
provided. This impacted the way the entire process 
was conducted in Tanzania. We were transparent 
and forthcoming with all of the potential investors 
with this information, asking about their preferences 
(including the options of having one manufacturing 
license with multiple distributors, or two 
manufacturing license). We also asked investors 
about geographic strengths, in preparation for 
potentially awarding two licenses. 
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IV. Process 
This section outlines the recommended steps to be taken for investor analysis and selection 
as outlined below in Exhibit 3. 
 
Exhibit 3. Investor Selection Process 
 
 
Before beginning the investor selection process, it is important to remember that much of the 
groundwork has already been laid during the commercialization strategy process. The 
information collected and documented during the commercialization strategy process should 
be referenced throughout the investor selection process as ATTC has already analyzed key 
questions—such as what type of market to target, who is driving demand, what level of 
investment will be required and what potential return exists, and also, who the potential 
partners in production, distribution and consumption are. The commercialization strategy 
document summarizes the key takeaways, which provide answers to these questions. ATTC 
should already have a good idea about the profile of the investor they are looking for based 
on interviews conducted during the commercialization strategy process and the fact that IITA 
has most likely already been working in-country for a few years performing Aflasafe test 
trials and certification. Additionally, the first set of potential applicants will likely come from 
the investor forum held during the commercialization process. Note that the Board’s approval 
of the Commercialization Strategy and any feedback, guidance or questions from the Board 
regarding their assumptions about the potential licensing arrangements will also frame the 
investor selection process in any given market, as highlighted further in Step 7. 
 
We have outlined below the basic process for investor selection and noted which ATTC 
team members should be involved in each step, including suggested timeframes. However, 
depending on the level of experience of the targeted businesses, availability of funds, and 
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business acumen within the ATTC team, an external consulting company may be asked to 
provide additional fundamental support during the various steps in this process. 
 
Step 1. Conduct Initial Filtering and Request Submissions of EOIs 
 
Objective To consolidate the list of potential investors, determine the initial filtering criteria and 
narrow the universe of candidates. After that, request Expressions of Interest (EOIs). 
Things to keep 
in mind 
 What companies have we met so far that would be strong candidates? 




Led by the Strategy Manager, advised by the Team Leader and supported by the Junior 
Strategy Associate:  
 2 weeks for consolidating the list of potential investors and conducting the initial 
filtering 
 1-2 days for reaching out to investors to request EOIs 
 1 week for firms to submit questions and requests for clarification 
 2-3 weeks to receive EOI submissions 
 
As discussed in the guide on Market Assessment and Strategy Development, begin 
identifying possible investors during the key informant interviews, ultimately deciding upon 
who to invite to the investor forum. During the investor forum, provide a survey asking firms 
whether they are interested to apply for the license. Encourage applications from potential 
investors who have strong manufacturing and/or distribution capabilities and are able to 
meet many of the criteria that you are seeking, such as high motivation and strategic 
alignment with their current business; a realistic understanding and readiness to take on the 
opportunity, adequate financial, marketing, and distribution capacity, and a strong 
management structure. Remember that it is possible to provide multiple licenses or pair 
investors, as discussed further in Step 7, and so an investor who is strong in either 
manufacturing or distribution, but not the other, should not be filtered out at this stage. 
 
It is likely that some applicants may be filtered out before EOIs have been requested. It may 
be quite clear from the outset that certain firms are not a good “fit” with the local context, 
ATTC goals, or country-specific goals. It is not only OK, but smart and efficient, to eliminate 
some firms at the initial stage in order to focus time and effort on soliciting EOIs from those 
that do fit. For example, you may choose to not request EOIs from applicants that exhibit 
deficiencies such as: 
 Businesses that do not have relevant experience in manufacturing, marketing or 
distribution of commercial products. 
 Non-profit organizations that will not be driven to maximize market penetration and 
sales.  
 Organizations that do not have experience or a presence in the target country.  
 Businesses or business owners that are barred or excluded due to poor reputation in 
organizational databases, such as the System for Award Management in the United 
States. 
 Businesses that do not have formal registration or authority to operate in the country. 
 Parastatal organizations, if you have sufficient applications from private sector 
partners. (In Kenya, for example, ATTC partnered with a parastatal organization 
given the political situation. This should be analyzed during the market assessment 
and strategy development process to determine the likelihood of the level of 
government involvement.) 
 
Investor Selection / Page 22 of 32
 
Objective To consolidate the analysis completed thus far into subjective rankings based on the 
evaluation criteria. 
Things to keep 
in mind 
 How will we rank? Will we assign points or look at the criteria and results holistically? 




Led by the Team Leader supported by the Manager 
 1 week to clean up notes and update evaluation criteria results for each investor 
 1 week to meet and compare rankings, and come to consensus 
 
Once you have reviewed the business plans and audited financials and conducted due 
diligence site visits, there should be ample data points and conclusions to evaluate investors 
against the evaluation criteria previously established and, as applicable, tailored for context. 
It may be helpful to have a way of highlighting each categorization and conclusion as 
positive, negative or neutral. This could be a quantitative ranking where points are assigned 
or a visual snapshot, such as color coding. When all of the results and conclusions have 
been written up for each candidate, you can then rank them. The rankings and conclusions 
form should be in a format such as Microsoft PowerPoint, Excel or Word that can be easily 
reviewed and understood by other decision-makers who were not part of the analysis. In 
particular, the resulting analysis should be shared with the ATTC Advisory Board and 
included as part of the Board presentation discussed in Step 8 below. It is also important to 
explain any aspect of the rankings that are more subjective or do not fit well within the 
original evaluation criteria, as well as identify open questions or key risks (if any) to flag 
coming out of the ranking process. Lastly, rank overall capacity using the evaluation criteria, 
as well as capacity in manufacturing versus distribution, as you could consider a special 
arrangement for multiple licenses or distribution support, as discussed further below. 
 
Step 7. Assess the Licensing Options 
 
Objective To assess our options for the business relationship and role of the investor(s) with whom 
we are considering. 
Things to keep 
in mind 
 Was there a clearly dominant investor in both manufacturing and distribution, or do we 
consider one investor strongest in manufacturing while another is stronger in 
distribution? 
 How does geography factor in? Will the selected investor have the ability to distribute 




Led by the Team Leader and Scientist, supported by the Manager 
 1 week to consider licensing options (to be conducted in tandem with the ranking of 
the investors) 
  
“Exclusivity” is noted as one of the evaluation criteria from Step 3 above. Consider 
discussing exclusivity when corresponding with applicants during the EOI and business plan 
phases.  Although the standard licensing arrangement is to have one exclusive licensee who 
manages both the manufacturing and distribution (Option 1), you can also consider whether 
the responsibility should be divided amongst multiple candidates and what the implication of 
that arrangement might be. For example, one candidate may have the clear capacity to 
manufacture, but they are not known for distribution or marketing. It may be beneficial to 
provide separate licenses for manufacturing and distribution or to recommend a partnership 
between one manufacturer and one or more distributors.  
 
 
Step 6. Rank the Investors 
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requirements and production specifics, and also ask technical questions of the businesses. 
In advance of traveling, (for the non-engineer visit) read through the business plans and 
develop a list of questions—to be most efficient with time, and to be able to hone in on any 
areas that require clarification (see box below for more ideas).  
 
 
When planning the site visit, it’s important to reflect on exactly what you want to verify during 
the visit, and design your questions accordingly. Your team should focus on analyzing the 
following key areas: 
 
 Scale and operations: Visiting the operations in person will provide an excellent 
sense of scale and manufacturing capacity. Does the company’s scale and 
sophistication seem appropriate for Aflasafe commercialization? Ask to see the 
relevant manufacturing equipment they currently have and confirm what will be 
purchased. 
 Market knowledge: The investor should not just regurgitate their commercialization 
strategy. They need to provide concrete examples which support their own strategy. 
Ask probing questions to test the depth of their market knowledge. 
 Relationships and distribution network: Ask the investor to provide specifics on their 
distribution plan and network—they will likely be more willing to discuss sensitive 
information verbally than in writing. Can the investor leverage their existing 
distribution network and succeed in Year 1? 
 Government relationship: Ask the investor how they plan to work with the 
government to promote public health campaigns as part of the awareness-raising 
component that will create demand. 
 Financial: Prepare to question any irregularities in the audited financials or seek 
clarification on the financial projections. Ensure that marketing costs included are 
sufficient. Ask about other investments they are planning to make, to see if there are 
upcoming financial pressures not reflected in past financial statements. 
 Transparency: The investor must be willing to share sufficient information to prove 
that they are prepared and willing to trust your team. How open was the company to 
letting you see operations? Were your questions answered and were follow-up items 
provided if not available during the meeting? 
 “Soft” factors: Look out for any signals from management that may indicate the 
company is hesitant, not ready for the challenge of commercializing Aflasafe, or does 
not consider Aflasafe a priority. Did they value your time? Did they prepare questions 
for you? How involved was the senior management team during the visit? How 
committed do they appear to be to this endeavor? Did their body language indicate 
discomfort or lack of sincerity? 
Lessons Learned 
 
If the registration process, the commercialization strategy, and the market intelligence are all developed by 
different teams or individuals, it’s critical to keep a central repository of the raw information gathered, or even 
start an FAQ early on of basic issues/discussions. Although some of the information may not be included in 
formal public documents, the details are still important to share with future teams to ensure there’s a common 
understanding of key issues, such as VAT applicability, implications of joint venture operations, country context 
views, background on the national government’s view on multi-national operations, etc. If this information is not 
shared and maintained in a central location, future individuals/teams may re-research and make determinations 
on the same issues with the same contextual background or interpretation of the analysis. It is helpful to see and 
understand how thinking might have evolved and why.  
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Next, reach out to the shortlisted firms to request that 
they submit a formal EOI (see box). EOIs are the 
initial applications submitted by the firms that are 
candidates for the Aflasafe license. Request EOIs 
from all applicants at the same time to ensure a fair 
and competitive process that will attract the best 
potential partners. Businesses should demonstrate 
their dedication and motivation to making this 
business line grow in step with IITA’s vision, 
ultimately ensuring the product will make it to the last 
mile.  
 
The EOI package submitted to ATTC by interested firms should include, but is not limited to, 
the following:  
 A written EOI that serves as a cover letter 
 Country registration verification 
 An organizational chart 
 Corporate governance documentation  
 Audited financials for the past three years 
 Proof of financial capacity (i.e., letter from a bank confirming a line of credit or 
agreement to lend for the Aflasafe investment, or a confirmation of cash reserves, 
equity or other financing if loans will not be needed) 
 
Set a deadline of 2-3 weeks to receive EOIs. Give potential investors sufficient time to 
respond, but they should also show the ability to meet a deadline. The deadline for receiving 
EOIs should not be extended significantly beyond your original deadline—this can be a 
factor in determining who is serious about the opportunity. The documents themselves 
should not be difficult to gather. Remember to set an intermediate deadline (e.g., 1 week) for 
firms to submit questions and requests for clarification. Answers to these questions should 
generally be distributed to all recipients of the EOI package, unless they relate to a particular 
firm’s specific situation.  
 
Step 2. Shortlist Candidates and Request Submissions of Business Plans  
 
Objective To ensure that ATTC receives strong business plans to adequately assess the investor 
candidates. 
Things to keep 
in mind 
 What is the capacity of candidates in this country, and is targeted support needed to 
enhance the business plan submissions? 




Led by the Strategy Manager, advised by the Team Leader and Engineer, and supported 
by the Junior Strategy Associate 
 
If business plans are prepared independently with no support from ATTC: 
 1 week – review EOIs, shortlist candidates, and request business plans 
 1 week – period to receive questions from businesses 
 3 weeks after end of Q&A period – final business plans due 
 
 If working session approach is utilized (see discussion further below): 
 1 week – Preparation for kick-off meeting 
 1 week after kick-off meeting – Business plan outline from investor due 
 1 business day after receiving outline from investor – Feedback on outline from ATTC 
due 
 2-3 weeks after receiving feedback on outline from ATTC – First draft of business 
plans and audited financials due  
 2-3 week after receiving draft business plan – Feedback on business plan by ATTC 
and stakeholders for input due* 
 2-3 weeks after receiving feedback from ATTC on draft business plan – Final draft of 
business plans due and presentation to ATTC 
Tips and Tricks 
 
The EOI package should make clear to 
firms that this is not an application for 
funding from IITA. Investors must find their 
own funding and clearly indicate a 
financing plan. The communications must 
also clearly state the point of contact 
within IITA and request the same of each 
applicant to ensure efficient 
communication channels.  
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* If site visits from specialists like the Engineers, or an invitation of perspective investors to 
a sample manufacturing site are possible, arrange after the draft business plans are 
submitted. Share feedback on a rolling basis if a specialist is not available to provide 
timely feedback.  
Shortlisting the EOIs. After receiving all EOI 
submissions (see box), ATTC should review and 
determine which of the EOI applicants to invite to submit 
a complete business plan and share copies of audited 
financials for the past three years. The number of EOIs 
submitted will depend on the level of interest by potential 
investors; there is no required amount of EOIs to be 
received although three to six is a reasonable 
expectation. In the event of receiving only one EOI, 
analyze the applicant to determine if it is appropriate to 
continue the investor due diligence for the single 
applicant, or whether to re-open the process. Assuming 
receipt of multiple applications, do not inform the 
shortlisted investors who they are competing against. We believe that the anonymity of 
competitors ensures fair competition.  
 
Upon receiving the EOIs, conduct another round of filtering, potentially filtering out: 
 
 Applicants that do not have proper management structure and operations (e.g., 
individuals looking to make investments but not willing to manage operations). 
 Very small businesses that do not have significant capital or access to capital, or that 
have operations that are too small to take on the Aflasafe investment in either 
manufacturing or distribution. 
 Businesses that were unable to 
submit packages that were 
complete or within the deadline. In 
these cases, use your own 
judgment to determine how deficient 
the submission was and whether 
you will still consider the 
submission. 
 
Submission of Business Plans. Once you 
have filtered the EOIs, the next step is to 
request business plans from shortlisted 
candidates (see box). The business plan is 
comprised of a narrative component, as 
well as a model in Microsoft Excel containing financial assumptions and projections. The 
business plan submission is the official method through which the applicant will demonstrate 
their capability to take on the Aflasafe investment. At this stage, provide a general overview 
of the evaluation criteria in the letter or email to investors requesting business plans. It is not 
recommended to share the comprehensive selection sub-criteria at this stage. Rather, share 
just the main categories of criteria. This will allow for some flexibility in the process (see Step 
3 below for details on evaluation criteria).  
 
As the companies attempt to outline their approach to the business, they will no doubt 
realize they have significant questions—about the manufacturing process, the equipment, 
potential alternatives in the manufacturing and sourcing process, and even about the viability 
of the technology—as they are starting to visualize this business line within their operations. 
Lessons Learned 
 
Having multiple perspectives when shortlisting 
potential businesses is important. Some businesses 
may not present a compelling EOI, but if there’s 
someone on the review panel with significant country 
experience, s/he could provide additional context to 
explain the significance of including that company in 
the shortlist. This scenario occurred in Tanzania, 
where the documentation provided by one of the 
applicants was lower in quality and thoroughness as 
compared to the others. However, ATTC knew that 
the applicants possessed a very strong distribution 
network that qualified it as a top candidate. Although 
this investor was not ultimately selected by ATTC, 
they participated in the full application process.
Lessons Learned 
 
In Senegal, we received only one 
EOI. Early interaction with one 
investor during the research and trial 
phase led to a reduction in the 
number of applicants. We learned 
that in order to ensure more 
competition and interest, we must 
promote the opportunity as fully open 
throughout the early stages of 
research and commercialization or 
else potentially interested firms will 
not engage. 
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their assertion that the financials present a true and fair view of the state of the audited 
entity’s financial affairs. The most important aspect of the audited financials for purposes of 
due diligence is the summary of the total sales, profit (gross and net), taxes, equity, debt, 
assets, cash flow, and inventory.  
 
To analyze these statistics, create a matrix in 
Microsoft Excel, which will allow for ease of 
comparison across years and across companies. 
This will enhance your ability to identify outliers 
and trends. For a sample matrix of the analysis of 
audited financials completed for the four finalists 
in Tanzania, please refer to Annex D. 
 
For example, if total sales or net profits decline in 
two or three of the three years displayed, question 
this negative trend. If the net profit margin is 
negative or under 1%, ask why. There may be a 
valid reason that indicates this is only temporary; however, if the investor is having 
challenges managing their core business, it may be a sign that they are not healthy enough 
to take on the Aflasafe investment. Exhibit 6 below contains relevant financial ratios to 
calculate and compare across investors: 
 
Exhibit 6. Financial Ratios for Analyzing the Audited Financials 
 
Financial Ratio & 
Calculation 
Definition 
Total Assets to Liabilities 
Ratio = Total Assets/Total 
Liabilities 
A high ratio for total assets to liabilities indicates that the company has either 
a strong level of assets or low liabilities or both. The higher the ratio the 
better, to show that the company has significant assets to cover its liabilities. 
Current Ratio = Current 
Assets/Current Liabilities 
The current ratio measures a company's ability to pay short-term obligations 
or those due within one year. The higher the ratio the better. 
Quick Ratio = (Current Assets 
- Inventories)/Current 
Liabilities 
The quick ratio measures a company's ability to pay short-term obligations or 
those due within one year with assets excluding inventories which are meant 
for sale and not to pay off liabilities. 
Cash Ratio = Cash/Current 
Liabilities 
The cash ratio measures a company's ability to pay short-term obligations or 
those due within one year using its most liquid assets which are cash and 
cash equivalents (i.e., if urgent payment is required).  
Total Debt to Equity Ratio = 
Total Debt/Total Equity 
The total debt to equity ratio is a measure of the degree to which a company 
is financing its operations through debt versus wholly-owned funds (i.e., 
equity). A very high ratio indicates high leverage, and potential risk.  
Inventory Ratio = 
Inventory/Sales 
The inventory ratio analyzes the level of inventory that an investor is carrying 
in a given year. A high ratio could indicate challenges with selling products. 
Step 5. Conduct Due Diligence Site Visits 
 
Objective To ask further questions, verify what is described in the business plan and observe first-
hand the management team and operations of each investor 
Things to keep 
in mind 
 What do we need to verify in person? 




Led by the Team Leader, Strategy Manager and Engineer 
 1-2 weeks prep time before travel (can be done in parallel with the business plan 
reviews) 
 1 day on the ground with each investor plus 1-2 days of travel (depending on distance 
between investors) 
 
Site visits are a key step in the evaluation process to verify what was included in the 
business plans by seeing physical operations in person and meeting team members. 
Request to meet with senior management as well as other technical experts. Consider 
sending an engineer to meet with the businesses to answer questions on capital expenditure 
Tips and Tricks 
 
Both working capital and long-term financing 
are required for the investment in Aflasafe.  
Debt financing can be expensive and hard to 
obtain. Make sure the investor has the 
capacity and financial health to take on more 
debt if it is required and included within their 
business plan. Keep in mind that audited 
financials may not tell the whole story. Is the 
firm making any other investments in new 
products that would impact its ability to take 
on the Aflasafe investment? 
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reputation and history of the investor. Tactfully look out for any “relationship issues” with 
other private sector partners or the government that would hinder their business potential. 
Also use the reference checks to determine how realistic their business plans are. Without 
giving out proprietary information to references, confidentially assess the feasibility of the 
investor’s capacity to take on the investment in Aflasafe production and distribution. To see 
the results of the investor selection criteria for the four finalists in Tanzania, please refer to 
Annex C. 
 
Step 4. Analyze the Audited Financials 
Objective To assess the financial health and capacity of each applicant. 
Things to keep 
in mind 
 Does the financial data show a steady trend or are there outliers? If there is outlier 
data, what does it signify about their regular business operations? 
 How do the financials compare across companies and what conclusions can we draw 
based on what we know about the differences in size and business models?  





Led by the Financial Analyst, and supported by the Team Leader and Manager 
 3 weeks for reviewing business plans and asking follow-up questions to investors (this 
is done in tandem with the review of the business plans) 
 Begin consolidating information by drafting slides for the Advisory Board while 
reviewing and comparing the audited financials 
 
A financial statement audit is the examination of an entity's financial statements and 
accompanying disclosures by an independent auditor. The result of this examination is a 
report completed by the auditor—the audited 
financials—attesting to the fairness of 
presentation of the financial statements and 
related disclosures. The audited financials 
allow you to assess the financial health and 
capacity of an applicant (see boxes on this 
page). Request the most recent three years of 
audited financials from each applicant. One 
year of financials is not sufficient because they 
don’t show trends. Three years of audited 
financials allow you to see how the financial 
health of the company has changed in the 
years leading up to today. 
 
While the format of the audited financial 
reports may vary from country to country, they 
will generally consist of similar information. 
The financials should contain an introduction of 
the financial firm who performed the audit and 
Lessons Learned 
 
Having multiple skill sets and perspectives on the evaluation team is useful. During the review of the Tanzania 
business plans, Chemonics ensured there was complementarity in the team’s skills. In particular, an individual 
with significant financial analysis experience was brought in specifically to review the audited financials and the 
financial component of the business plans once all of the financial documentation was received. This individual 
had not been very involved in the process to date and didn’t have the entire context and/or biases regarding the 
relationships developed with all of the businesses. This helped to ensure thorough and comprehensive review 
and analysis from a perspective more akin to how the Board might be approaching the information and decision—
some Board members may primarily be piecing together the comparative analysis from the financial 
documentation. Bringing in fresh perspectives can ensure an unbiased review—not based on previous 
engagement with the investors—and anticipate questions from the Board. 
Tips and Tricks 
 
This is not a franchise business model or complete 
turnkey operation. In order for the chosen business 
partner to be successful, it takes marketing strategy, 
distribution networks, financial investment, and 
market relationships and knowledge. Developing 
and/or expanding these networks takes time and 
money. If a potential investor already has a 
struggling business line, or a struggling core 
business, this new business line with Aflasafe will 
not be a savior, or a quick and easy cash cow. As 
much as there are definite advantages to working 
with IITA, (proven technology/product, technical 
expertise, international research institute 
reputation), this is still a new business line. As with 
any new business line, there’s a significant 
investment of time, strategy, and money required 
during the first few years and the chosen investor 
must be willing and able to meet this challenge.  
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Support and timely feedback from the engineers and scientists at this stage can be critical to 
quickly addressing and mitigating any fears the company may have, but it will also give 
ATTC insight into whether they are willing to adhere to the required quality standards and if 
they have the capacity to be a strong business partner—one who can challenge the 
accepted knowledge to find efficiencies as opposed to challenging just for the sake of 
challenging. 
 
As it is important to ensure that you are asking for and receiving sufficient information from 
which to evaluate and compare the potential investors, templates for both the narrative and 
financial projections are provided to solicit the same information across all of the shortlisted 
candidates. Ideally, you will receive a uniform level of information for comparison purposes. 
You may decide to pre-fill some of the information in the business plan narrative to guide the 
responder; for example, the template could include information from the commercialization 
strategy on the target market and recommended strategies and market segments. However, 
leave sufficient space for the investor to show their own analysis, commitment to and 
understanding of the product, and approach to entering the market. The template allows 
your team to evaluate the investor and should not be pre-filled with too much information, 
just enough to be clear in what is expected of the investor. The business plan narrative 
template and guidance letter from IITA is provided as Annex A and the business plan 
financial projections template is provided as Annex B.  
 
Business Plan Narrative. The narrative component of the business plan requires applicants 
to display their knowledge of Aflasafe, an understanding of the marketplace, and the ability 
to map out a strategic plan and the resources needed for the investment. Specifically, the 
narrative template contains the following sections: 
 
 Executive Summary 
 Description of the business 
 Potential markets and competitive analysis 
 Strategic plan 
 Manufacturing plan 
 Marketing and distribution 
 Financial plan 
 Legal and governance structure 
 Potential risk and mitigation strategies 
 Acknowledged weaknesses and plan to address them 
 Action plan 
 Annex 
 
Business Plan Financial Model. Request a financial model from the investor candidate that 
includes anticipated costs and targets. Aflasafe is an investment opportunity with a return 
over a medium-term horizon, therefore, ask for a five-year financial model as part of the 
business plan. To support the process, consider providing a template for the financial model, 
containing the following sections: 
 
 A summary of the commercialization process 
 Annual production targets 
 Annual marketing costs  
 A procurement schedule 
 A staffing plan 
 Detailed financial projections (costs and revenues) 
 A break-even point analysis 
 A sensitivity analysis 
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 Potential risks and mitigation strategies 
 Potential partners 
 Action plan calendar 
 
As all investors will utilize some form of financial model for projections and budgeting within 
their regular operations outside of Aflasafe, be prepared to accept different formats for the 
financial projections. The financial model template demonstrates to the investor the minimum 
level of detail required in order to analyze their projections. If the investor would like to 
submit a more detailed financial model, we recommend that you accept the additional detail. 
Many formats are acceptable, as long as they are organized so that the data is easily 
understood. If the investor cannot provide a financial model that is clear or complete, this is a 
red flag. The Aflasafe investment requires a level of capacity and planning that must be 
backed up by a financial model to prove that the investor understands the capital required as 
well as the risks and potential gains for the investment.  
 
Upon receipt of the business plan narrative and financial projections, you must conduct an 
initial review of both to determine if there is anything missing or incomplete, to be sure you 
have complete submissions to analyze. Don’t forget to respect the confidentiality of the 
information submitted by applicants. The ability to trust each other will be key to receiving 
quality information and establishing a 
good relationship. 
 
If you expect the capacities of the 
applicants to be relatively low, you can 
offer support to investors during the 
business plan development process by 
organizing working sessions. In the past, 
the Chemonics and Dalberg teams 
offered support from the perspective of 
consulting firms. This provided some 
distance from the IITA team and reduced 
the potential for bias. However, if a 
consulting team is not involved, you can 
and should offer this same support. If you 
are providing insights to one investor 
regarding how to prepare the business 
plan, in fairness, try to provide the same information to all applicants. This will also increase 
the chances that you receive high quality submissions from everyone.  
 
What each potential investor does with the information—i.e., how they apply it to their 
business plan—is up to the investor. Potential investors will interpret and apply the same 
information differently, but at least each one will have the same access to the information 
and no favoritism or unfair advantage will be shown. There will always be some investors 
who will want to have meetings, seek further insight, and try to figure out what the ATTC 
business advisors are thinking; these are the ones who recognize that the business plan 
support meetings amount to free management consulting support. Investors who do solicit 
advice from ATTC show initiative and the 
determination to succeed. These requests 
provide a window into the way they do 
business—and how open the company is to 
feedback and collaboration (see box below). 
Giving targeted support to investors will 
probably lengthen the timeline for completion 
of the business plan given the extra drafts 
Lessons Learned 
 
Many potential companies are family-owned 
businesses. Across the globe, family-owned 
businesses are notorious for being slow to accept 
external advice and have a hard time adapting to 
change. This became clear during the due diligence 
phase, in assessing how the companies responded to 
the feedback provided throughout the entire process.   
Lessons Learned 
 
There are competing priorities with setting a timeframe that 
is too aggressive versus one that is too lax.  
 
In the case of Tanzania, the Board wanted to award the 
TTLA in Tanzania within a 2.5 month timeframe from their 
approval of the Commercialization Plan, which meant less 
than 6 weeks for the businesses to submit all final 
documents and less than 2 weeks for the Board to 
evaluate the business plans, prepare presentations, and 
convene a Board meeting. Thankfully, the Board listened 
to feedback from the potential investors and adjusted their 
expectations, adding an additional 3 months to the 
process. With the end-of-year holidays, it took the entire 
five months in between Board meetings for the investors 
to finalize their plans, and it took another 7 weeks after the 
Board meeting to finalize the TTLA.  
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 Investor aligns with ATTC’s mission to be a leader in 
innovation of agricultural technologies in Tanzania 
 Business plan details a market-driven approach for driving 
uptake of Aflasafe 
 Investor is aware and sensitive to aflatoxin contamination in 
Tanzania 
Realistic Understanding & 
Readiness 
 Investor possesses financial capacity to invest in Aflasafe 
manufacturing & distribution in 2019 
 Investor possesses managerial and operational capacity to 
launch Aflasafe production in 2019* 
 Investor is prepared to implement its business plan in next 
3 to 6 months 
Financial: Health, Scale, Access, 
Management 
 Investor possesses financial capacity to invest in Aflasafe 
manufacturing & distribution in 2019 
 Business plan details the source of funds or financing to 
make an investment in manufacturing & distribution 
 Financial plan and forecast show financial acumen and 
ability to turn a profit 
Marketing and Distribution  Business plan details a market-driven approach for driving 
uptake of Aflasafe 
 Investor has experience marketing new products to 
processors and consumers in Tanzania 
 Investor has relationship with processors, aggregators, and 
farmers 
 Business plan outlines existing distribution channels to 
reach target market; or detailed plans to create them 
Management Team   Management team is dedicated to Aflasafe business, 
marketing, awareness, and advocacy*  
 Team has positive relationships with public sector 
institutions 
 Balanced patience with action and strategic thinking* 
 Ability to communicate the vision and approach internally 
and externally*  
Exclusivity & options  Investor is open to working with other partners 
*These sub-criteria will be evaluated in particular during on-site due diligence visits as described in 
Step 5 below. 
 
Based on the established evaluation criteria, begin to 
analyze each applicant’s qualifications in detail (see 
boxes). Pay particular attention to any deficiencies or “red 
flag” issues and be prepared to ask the investor to clarify as 
needed via targeted follow-up questions. There may be a 
valid explanation, thus removing the red flag, or perhaps 
there is a mitigation plan to take note of.  
 
At this stage, also use IITA’s network to conduct informal 
reference checks on the investor, in particular if the investor 
is not well known to ATTC. It is important to know the 
Tips and Tricks 
 
Question the assumptions in the 
business plan!  We must scrutinize 
and have a discerning eye 
regarding any projections. We 
also need to check for accuracy.  
The financial analyst can focus on 
the business plan financial model 
while the Manager can focus on 
the business plan narrative. 
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 Up to 3 weeks should be allowed for reviewing business plans and asking follow-up 
questions to investors as needed, although this is generally not advertised to investors 
in advance as part of the process 
 Begin consolidating information by drafting slides for the Advisory Board while 
reviewing and comparing business plans 
 
Upon receiving the final business plans, the real analysis can begin. Establishing evaluation 
criteria enables an objective comparison of the merits of each proposal and firm. The criteria 
will help determine follow-up questions to ask of the investors if the information submitted is 
not clear in any way. The criteria may be influenced by the guiding questions and key 
takeaways developed in the strategy document as part of the commercialization process.  
 
It is recommended to allow some flexibility in the sub-criteria (as indicated in the right side of 
the table below) as you will learn about more critical nuances within the country context and 
potential approaches as you begin comparing investors. To maintain the integrity of the 
evaluation process, any additional sub-criteria, changes to the sub-criteria, or clarification of 
expectations within the sub-criteria should be agreed upon by the evaluation panel in 
advance of each assessment and should be applied evenly to all potential candidates. 
Exhibit 5 below provides a sample of the evaluation criteria from the recent investor selection 
process in Tanzania. The refinement of the evaluation criteria is an iterative process, with 
incremental changes and progress strengthening the selection process as it progresses. No 
doubt the process will continue to evolve over time, as we learn from each experience.  
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and reviews, so keep setting deadlines in order to keep the process moving in a timely 
manner (see box). In Nigeria, for example, the Dalberg team had three sessions with the 
prospective investor HarvestField. Exhibit 4 below displays the process followed in Nigeria 
for providing targeted support to the business plan development.  
 





Investors are also required to submit the three most recent years of audited financials. 
Reviewing the audited financials will allow for the determination of the health of the 
applicant’s organization from a financial perspective—to assess if they have sufficient cash 
flow or borrowing ability to finance the initial capital assets, working capital to start 
production, and an ability to implement an aggressive marketing strategy and distribution 
plan. If requested by the prospective investor, IITA would sign an NDA to ensure data 
privacy. 
 
Step 3. Evaluate the Business Plans utilizing the Evaluation Criteria 
 
Objective To thoroughly analyze the business plan submissions and evaluate the quality of the 
proposals submitted 
Things to keep 
in mind 
 Are there any unique qualities or characteristics that an investor operating in this 
country should possess? 
 While reviewing business plan submissions, how can we compare strengths and 




Led by the Team Leader and Strategy Manager, supported by the Junior Strategy 
Associate and Financial Analyst 
 2-3 days for updating and contextualizing the detailed selection criteria (flexibility to 
update/change before reviewing business plans) 
